Market News Video
MNV MNV 10 Stocks Crossing Above Their 200 Day Moving Average
Free Dividend Report - Top Ranked Stocks

Featured MNV Articles:

The New #8 Most Shorted Dow Component: Visa
Thursday, December 28, 8:27 AM ET, by Market News Video Staff

The most recent short interest data has been released for the 12/15/2017 settlement date, and ...

February 2018 Options Now Available For Abbott Laboratories (ABT)
Thursday, December 28, 10:35 AM ET, by Market News Video Staff

Investors in Abbott Laboratories (ABT) saw new options become available today, for the February 2018 ...

Pfizer a Top 25 Dividend Giant With 3.74% Yield (PFE)
Friday, December 29, 7:49 AM ET, by Market News Video Staff

Pfizer Inc (PFE) has been named as a Top 25 ''Dividend Giant'' by ETF Channel, ...

Ex-Dividend Reminder: Bristol-Myers Squibb, Brixmor Property Group and Kite Realty Group Trust
Tuesday, January 2, 9:56 AM ET, by Market News Video Staff

On 1/4/18, Bristol-Myers Squibb Co. (BMY), Brixmor Property Group Inc (BRX), and Kite Realty Group ...

Vanguard Value ETF Experiences Big Outflow
Tuesday, January 2, 10:49 AM ET, by Market News Video Staff

Symbols mentioned in this story: VTV, PG, PFE, DWDP Exchange traded funds (ETFs) trade just ...

  More articles:  1 2 next »

Bristol-Myers, Pfizer Announce Positive Results; An FDA Approval for Pfizer

By Market News Video Staff, Monday, August 29, 8:47 AM ET
Play Video: The Importance of ETFs

If the video does not load after a few moments, Upgrade to the Latest Flash Player.

Bristol-Myers Squibb (NYSE:BMY) and Pfizer (NYSE:PFE) announced over the weekend positive results in a Phase 3 trial that compared Elquis to warfarin for the prevention of stroke or systemic embolism in patients with atrial fibrillation and at least one risk factor for stroke.

The companies said the drug showed Elquis significantly reduced the risk of stroke or systemic embolism by 21%, major bleeding by 31%, and mortality by 11%. Separately, Pfizer said that the Food and Drug Administration has approved Xalkori capsules, which the company calls the first-ever drug targeting anaplastic lymphoma kinase, or ALK, for the treatment of locally advanced or metastatic non-small cell lung cancer that is ALK-positive.

Pfizer noted that lung cancer is responsible for more deaths each years worldwide than any other type of cancer, and the drug offers a new treatment option for a subset of patients with the disease.

The FDA gave the drug accelerated approval, and Pfizer is conducting post-marketing clinical trials to further evaluate its clinical benefit. Pfizer partnered with Abbott Laboratories’ (NYSE:ABT) Molecular business on a diagnostic test for ALK, which was approved simultaneously with the drug. Xalkori is available immediately through some pharmacies.

Top Six Most Viewed Stories This Week @ Market News Video:

This Article's Word Cloud:   Abbott   Administration   Elquis   Food   Molecular   Myers   NYSE   Pfizer   Xalkori   advanced   approved   atrial   benefit   business   cancer   capsules   clinical   compared   diagnostic   disease   drug   each   embolism   evaluate   further   least   lung   lymphoma   marketing   mortality   offers   over   partnered   patients   pharmacies   positive   risk   said   small   some   stroke   subset   systemic   targeting   that   treatment   which   with   worldwide   years
About Us - Advertise - Contact Us - Embedding Videos - Licensing Videos - Partners - mRSS / RSS Feed - Terms of Use - Privacy Policy - Video Widget
Home  |  Analyst News  Dividend Report  ETFs  Insider Report  Large Caps  Market Movers  Week Ahead Report  Weekly Market Wrap
MNV MNV Stock Message Boards Stock Market Definitions

Bristol-Myers, Pfizer Announce Positive Results; An FDA Approval for Pfizer | Market News Video | Copyright © 2008 - 2018, All Rights Reserved

Any ideas and opinions presented in all Market News Video clips are for informational and educational purposes only, and do not reflect the opinions of BNK Invest, Inc. or any of its affiliates, subsidiaries or partners. In no way should any content contained herein be interpreted to represent trading or investment advice. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. Read Full Disclaimer.